Small-molecule Articles | Smolecule

Home / Articles / CDK6 inhibitors/antagonists

Mar

22

Potential Treatment for Multiple Myeloma - CDK6 upregulation as a druggable target (March 2022)

cdk6-inhibitors-antagonists

Potential Treatment for Multiple Myeloma - CDK6 upregulation as a druggable target (March 2022)

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In multiple myeloma, the overgrowth of plasma cells in the bone marrow can crowd out normal blood-forming cells, leading to low blood counts. Myeloma cells also interfere with cells that help keep bones strong.

1